Sildenafil, for the treatment of erectile dysfunction, is one of the first products that has made its way successfully from basic NO (nitrous oxide) research, to clinical routine therapy. Sidenafil, part of the Milestones in Drug Therapy series, presents the major breakthroughs in the field of NO physiology and pharmacology that led to the development of the drug, as well as clinical applications in one source guide.

Written by leading experts in the field, each chapter covers aspects of clinical use and experience, pharmacokinetics, pharmacodynamics, biochemistry, and cultural science.

Inhalt

From the contents: The detection and developement of sildenafil.- Sildenafil, pharmacology of a highly selective PDE-5 inhibitor.- Sildenafil, gold-standard in the treatment of erectile dysfunction.- Sildenafil in the prevention and treatment of erectile dysfunction after prostate cancer treatment.- ED-treatment with sildenafil improves quality of life and partnership.- Sildenafil in ED Therapy in patients under psychopharmacological drugs.- Cardiovasculare safety of sildenafil in the treatment of erectile dysfunction.- Sildenafil in female sexual dysfunction.- Penis pathology , as mixed urolgical ED under NO managing drugs, the mono and multiple therapy approach.- Cardiovascular events under Sildenafil and other NO managing drugs.- Sildenafil in pulmonary hypertension.- Sildenafil improves endothelial dysfunction.- Sildenafil in rehabiltative procedures of neurologically disease patients.- The PILRS-Study: The PDE V Inhibitor low response study in patients with ED.- The cultural impact of Sildenafil